Amira makes appointments to scientific advisory board
This article was originally published in Scrip
Executive Summary
Amira Pharmaceuticals, a US small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory diseases, has appointed Dr Paul Anderson, Professor Jerold Chun and Professor Andrew Tager to its scientific advisory board. Dr Anderson has more than 40 years' pharmaceutical research and managerial experience, including 30 years at Merck Research Laboratories. Dr Chun is a professor at The Scripps Research Institute in La Jolla, California, while Dr Tager is an assistant professor at Harvard Medical School in the pulmonary and critical care unit of the Massachusetts General Hospital, and co-director of the hospital's interstitial lung disease programme.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.